FDA Finds Paclitaxel Mortality Risk In Panel Lead-Up
Executive Summary
Preview documents from the US FDA show the agency is aware of the mortality risk linked to paclitaxel-coated devices, but stop short of suggesting the devices be removed from the market.
You may also be interested in...
FDA Tells Providers To Limit Use Of Paclitaxel-Coated Stents
New US FDA analysis of paclitaxel-coated devices to treat peripheral arterial disease matches previous reports of an increased death risk tied to use of the devices. The agency is encouraging providers to look to other treatment options while analysis continues.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.